Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection

Naing, Cho; Sitt, Than; Aung, Aye Td; Aung, Kyan

doi:10.1097/md.0000000000001234

Cited by 7 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found 36% SVR with the initial pegIFNα2a+RBV regimen (Table 2), similar to previous reports in Mexico of 32.5% (Sandoval-Ramirez et al, 2015). Fifty one percent of the non-cirrhotic patients, and 68% of those with low baseline viral load achieved SVR with pegIFNα2a+RBV (Table 3), similar to other publications (Enomoto & Nishiguchi, 2015;Naing et al, 2015). Diabetes did not associate with failure of pegIFNα2a+RBV treatment: 34.2% of diabetic patients achieved SVR (Table 3), similar to SVR of all the cohort.…”

Section: Discussionsupporting

confidence: 90%

Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy

Meléndez-Mena

Mendoza-Torres

Sedeño-Monge

et al. 2021

PeerJ

View full text Add to dashboard Cite

Background Direct Acting Antivirals (DAAs) represent a large improvement in the treatment of chronic hepatitis C, resulting in <90% sustained virological response (SVR). There are no reports on the real-world DAA response for Mexico and few reports exist for Latin America. The aim of the study was to report SVR, and immediate benefits with the DAA treatments sofosbuvir, ledispavir, with/without ribavirin (SOF/LDV ± RBV) and ombitasvir, paritaprevir, ritonavir, dasabuvir with/without RBV (OBV/PTV/r/DSV ± RBV) in patients with viral genotype 1a or 1b, and who did not respond to previous peginterferon/ribavirin (PegIFNα2a+RBV) therapy. Methods A descriptive, ambispective, longitudinal study was conducted. A cohort of 261 adult patients received PegIFNα2a+RBV therapy before 2014; 167 (64%) did not respond, 83 of these were subsequently treated with SOF/LDV ± RBV or OBV/PTV/r/DSV ± RBV. Child-Pugh-Score (CPS), Fibrosis-4 (FIB-4), and AST to Platelet Ratio Index (APRI) were evaluated before and after treatment. Results SVR with PegIFNα2a+RBV was 36%, and 97.5% with DAAs. CPS, FIB-4 and APRI improved significantly after DAA treatment, mainly because of liver transaminase reduction. Conclusions DAA treatment showed excellent SVR rates in Mexican patients who had not responded to PegIFNα2a+RBV therapy. Improvement in CPS, FIB-4 and APRI without improvement in fibrosis was observed in cirrhotic and non-cirrhotic patients, as well as considerable reduction in liver transaminases, which suggests a reduction in hepatic necroinflammation.

show abstract

Section: Discussionsupporting

confidence: 90%

Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy

Meléndez-Mena

Mendoza-Torres

Sedeño-Monge

et al. 2021

PeerJ

View full text Add to dashboard Cite

show abstract

“…Moreover, high fibrosis scores did not influence SVR among patients treated with triple combination therapy ( P =.19) (Table ). Historically, 24 or 48 weeks of PEG‐IFN+RBV combination therapy has yielded SVR rates of about 75‐90% across all HCV genotypes in Myanmar . Results from the NEUTRINO study showed SVR rates of 90% after 12 weeks of triple combination therapy for patients with genotypes 1 and 4‐6, and a significantly higher rate of SVR among patients without cirrhosis .…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of sofosbuvir‐based direct‐acting antiviral regimens for hepatitis C virus genotypes 1‐4 and 6 in Myanmar: Real‐world experience

Hlaing

Mitrani

Aung³

et al. 2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…Direct-acting antiviral (DAA) therapy has high cure rates and a substantially reduced side effects profile compared to dual therapy with pegylated-interferon (peg-IFN) and ribavirin (RBV), and has revolutionized HCV treatment paradigms in many countries[2]. However, DAA treatment is only just beginning to enter the market in Myanmar, leaving peg-IFN and RBV therapy as a viable option[3,4]. …”

Section: Introductionmentioning

confidence: 99%

Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country

Hlaing¹,

Banerjee²,

Mitrani³

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo investigate peg-interferon (peg-IFN) and ribavirin (RBV) therapy in Myanmar and to predict sustained virologic response (SVR).METHODSThis single-center, open-label, study was conducted in Myanmar between 2009 and 2014. A total of 288 patients infected with HCV genotypes 1, 2, 3 and 6 were treated with peg-IFN alpha-2a (180 μg/wk) or alpha-2b (50 to 100 μg as a weight-based dose) and RBV as a weight-based dose (15 mg/kg/d). Treatment duration was 48 wk for genotypes 1 and 6, 24 wk for genotype 2, and 24 or 48 wk for genotype 3 based on rapid virologic response (RVR). Those co-infected with hepatitis B received 48 wk of therapy.RESULTSOverall, SVR was achieved for 82% of patients and the therapy was well tolerated. All patients achieved SVR at equivalent rates regardless of HCV genotype (P = 0.314). Low fibrosis scores (P < 0.001), high baseline albumin levels (P = 0.028) and low baseline viral loads (P = 0.029) all independently predicted SVR. On the other hand, IL-28B TT and CC genotypes were not found to significantly predict SVR (P = 0.634; P = 0.618). Among those who completed treatment, the occurrence of RVR showed a > 96% positive predictive value for achieving SVR. Treatment duration did not significantly impact the likelihood of achieving SVR for patients infected with genotype 3 HCV (P = 0.371). The most common adverse events were fatigue (71%) and poor appetite (60%). Among patients with genotype 3 HCV, more patients in the 48-wk treatment group required erythropoietin than in the 24-wk treatment group (61.1% vs 49.2%).CONCLUSIONSVR rates were high with peg-IFN and RBV therapy in Myanmar. Fibrosis scores, baseline albumin, HCV RNA levels and RVR independently predicted SVR.

show abstract

Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection

Abstract: Supplemental Digital Content is available in the text

Cited by 7 publications

References 41 publications

Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy

Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy

Safety and efficacy of sofosbuvir‐based direct‐acting antiviral regimens for hepatitis C virus genotypes 1‐4 and 6 in Myanmar: Real‐world experience

Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country

Contact Info

Product

Resources

About